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Abstract 
Background. Malnutrition is very prevalent among patients with chronic renal failure. The role of derangements 
in the gut–brain axis for regulation of appetite in the genesis of anorexia of these patients has not been 
adequately investigated.  
Design. Following a randomized, crossover design, we analysed plasma levels of peptide YY (PYY) 1–36 and 
PYY 3–36 both fasting and after a standardized oral mixed meal or intraperitoneal glucose infusion in 10 stable 
uraemic patients undergoing peritoneal dialysis and 8 healthy controls, matched for age, gender and body mass 
index.  
Main results. Median baseline plasma levels of PYY 1–36 in the different provocation tests oscillated between 406 
and 460 pg/mL in patients, as compared with 73 and 100 pg/mL in controls (P < 0.001). Corresponding values 
for PYY 3–36 oscillated between 235 and 267 pg/mL in patients, versus 56 and 70 pg/mL in controls (P < 0.001). 
The association of high levels of PYY 3–36 and normal levels of acylated ghrelin (when compared with healthy 
controls) configurated a markedly pro-anorexigenic pattern in patients. Neither oral intake nor intraperitoneal 
glucose resulted in significant changes in plasma levels of PYY 1–36 or PYY 3–36 in subjects with renal failure, in 
contrast with the expected postprandial rise observed in healthy controls (41% for PYY 1–36 , P = 0.04 and 32% 
for PYY 3–36 , P = 0.02, median values).  
Conclusions. Baseline plasma levels of PYY 1–36 or PYY 3–36 are markedly elevated in patients with renal failure 
undergoing peritoneal dialysis. Provocation studies disclose a marked disregulation in the postprandial secretion 
of these anorexigenic peptides, when compared with healthy controls. These findings may contribute to clarify 
the complex pathogenesis of anorexia of chronic renal failure.  
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Introduction 
Malnutrition is highly prevalent among patients with chronic renal failure (CRF), and represents a 
consistent marker of poor survival in this population [1]. Many factors beyond inadequate nutrient 
intake contribute to the pathogenesis of this complication [2], but anorexia is a prominent feature of 
the uraemic syndrome. Dialysis therapy is often unable to correct, and may even worsen, this 
symptom [3–5]. During the last decades, considerable attention has been devoted to the potential role 
of derangements in the mechanisms that regulate short- and long-term nutrient intake and utilization [ 
6] in the pathogenesis of the nutritional disorders of CRF. Resistance to the anabolic effects of insulin 
is a well-known contributor to malnutrition, in this setting [2]. Also, distorted secretion of 
adipocytokines may compromise the nutritional status of these patients [7]. Plasma leptin levels are 
consistently elevated in patients with CRF, particularly in those treated with peritoneal dialysis (PD) 
[8], but the actual contribution of this disorder to anorexia and malnutrition of uraemia is 
controversial [9,10].  
 
The role of potential derangements of the gut–brain axis in the genesis of disorders of appetite of 
patients with CRF has not been established. Plasma levels of total (but not acylated) ghrelin have 
been found to be increased in CRF [11], and a subnormal suppression of the secretion of this 
orexigenic peptide by oral intake has also been observed in these patients [12]. On the other hand, 
exogenous administration of ghrelin is able to increase appetite in anorexic patients with CRF [13]. 
Other gut peptides implicated in the regulation of appetite have not been adequately studied in CRF, 
so far.  
 
Peptide YY (PYY) is released by intestinal L cells in response to meals, both as the full 36 amino 
acid molecule (PYY 1–36 ) and as the 3–36 fragment (PYY 3–36 ), which seemingly brings most of the 
biologic activity of the hormone. PYY appears to play a significant role in the short-term regulation 
of appetite [14,15], acting as a break to oral intake by complex mechanisms, which include 
stimulation of vagal afferents and a direct interaction with the receptor Y2 (Y2R) of the hypothalamic 
arcuate nucleus [16]. Exogenous administration of PYY reduces oral intake in rodents [17] and obese 
humans [18], and plasma PYY levels are elevated under several low-appetite conditions, including 
anorexia nervosa [19]. Altered PYY secretion patterns could play a role in the pathogenesis of 
anorexia of CRF, but this possibility has not been adequately investigated. We have performed a 
crossover randomized trial, with the aim of disclosing potential derangements in the response pattern 
of PYY to a standardized mixed meal and to hypertonic glucose-based PD-dialysate, in a group of 
uraemic patients undergoing chronic PD.  
Population and method 
General design 
Following a crossover design, 10 non-diabetic patients undergoing chronic PD therapy and 8 
healthy controls, matched for age, sex and body mass index, were scrutinized for baseline PYY (1–36) 
and PYY (3–36) levels, as also for the reponses of these peptides to a standardized oral feeding, 
hypertonic glucose-based dialysate and orally administered placebo. Thus, every patient underwent 
three tests, and every control two tests (oral feeding and placebo), with a time span of 40 days for the 
whole sample retrieval period. Tests were carried out in a randomized order. The study protocol 
fulfilled the requirements of the ethical committee of our centre, and a written informed consent was 
obtained from both patients and controls.  
Subjects 
Patients were randomly selected from our population undergoing chronic PD therapy, after 
applying the following exclusion criteria: diabetes mellitus, age <30 or >70 years, significant clinical 
events during the previous 3 months and unwillingness or inability to cooperate. Controls were 
selected from a pool of healthy volunteers available to the endocrinology unit of our centre. Both 
groups were comparable in regard to age [median 56 years (range 36–65) for patients versus 53 (36–
61) for controls], gender (50% males in each group) and body mass index [24.7 kg/m 
2
 (20.7–32.0) 
for patients versus 25.7 (20.1–31.3) for controls]. Patients had been treated with PD for a median of 
11 months (3–63), preserving a median glomerular filtration rate (GFR) (as estimated from the mean 
of urea and creatinine clearances) was 4.2 mL/min (0.0–8.8) in patients. Three patients were 
oligoanuric at the time of the study. No patient reported overt anorexia or suffered a significant 
clinical event during the study period.  
Protocol 
Patients were instructed to perform a single nighttime PD exchange using either 1.36% glucose- 
or icodextrin-based dialysate (Baxter®, Deerfield, IL, USA), the day before the test. After an 
overnight fast, all tests started between 8:30 and 9:00 a.m. Patients and controls were at rest in a 
sitting position, and a peripheral venous line was obtained. Thirty minutes later, both received the 
following on three different days.  
 
 A standardized oral feeding, consisting of 400 mL of Isosource Energy (Novartis®, Zurich, 
Switzerland), containing 5.7 g of protein, 6.2 g of lipid and 20 g of carbohydrate per 100 mL, for 
a total caloric content of 158.8 kcal/100 mL (14.4% protein, 35.1% lipid, 50.4% carbohydrate). 
The first PD exchange of the day was delayed until the end of the test, in patients. All the patients 
and controls were able to eat the whole test meal. 
 A PD exchange consisting of 2 L of dialysate (Baxter ® , Deerfield, IL, USA) with a glucose 
concentration of 3.86 g/dL (patients). Patients were kept fasting until the end of the test.  
 Orally administered placebo (400 mL of tap water). Patients/controls were kept fasting and, again, 
the first PD exchange of the day was delayed until the end of the test in patients. 
 
We obtained blood samples for PYY (1–36) , PYY (3–36) , total and acylated ghelin, leptin, insulin 
and growth hormone (GH) at baseline and then at 30, 45, 60 and 120 min. Data concerning the 
responses of total and acylated ghrelin, leptin, insulin and GH during these tests have been previously 
published[ 12 ]. Baseline hormonal values (except PYY levels) have also been presented in the 
aforementioned article.  
Sample management and laboratory methods 
All blood samples were immediately centrifuged, separated and frozen at −80°C. Samples 
destined for determination of ghrelin and PYY levels were specifically retrieved to chilled tubes 
containing aprotinin and EDTA-Na, and then immediately centrifuged at 4°C, separated to aliquots 
and frozen at −80°C. 
 
For estimation of the main scrutinized hormones, we used the following specific commercial 
assays:  
 
 PYY (1–36) (RIA, Linco, St Charles, MO, USA) (intra- and inter-assay variation coefficients 2.9% 
and 5.5%, respectively; lower detection limit 10 pg/mL)  
 PYY (3–36) (RIA, Linco, St Charles, MO, USA) (intra- and inter-assay variation coefficients 6.4% 
and 7.7%, respectively; lower detection limit 20 pg/mL)  
 Total ghrelin (RIA, Phoenix Pharmaceuticals, Belmont, CA, USA) (intra- and inter-assay 
variation coefficients 5.3% and 13.6%, respectively; lower detection limit 10 pg/mL) 
 Acylated ghrelin (RIA, Linco, St Charles, MO, USA) (intra- and inter-assay variation coefficients 
6.5% and 9.6%, respectively; lower detection limit 10 pg/mL). 
 
Other hormonal laboratory estimations included leptin (RIA, Mediagnost, Tübingen, Germany), 
insulin (RIA, CIS Bio International, Cedex, France), GH and IGF1 (RIA, Nicholls Inst. Diagnost., 
San Juan Capistrano, CA, USA) and cortisol (Chemoluminiscence, ADVIA Centaur System, Bayer, 
Leverkusen, Germany). We also estimated baseline (placebo test) plasma levels of interleukin-6 
(ELISA, R&D Systems, Minneapolis, MN, USA) and high-sensitivity C-reactive protein (hsCRP) 
(Immunoturbidimetry, Roche Diag., Mannheim, Germany). Plasma levels of albumin, prealbumin, 
cholesterol, triglycerides and glucose (as also dialysate glucose levels) were estimated using a 
standard autoanalyzer. 
  
Secondary calculations 
The time courses of plasma PYY (1–36) and PYY (3–36) levels after the different tests were analysed 
in absolute terms and also as a percent change versus baseline, the latter to overcome potential biases 
induced by potentially different baseline plasma levels of both peptides in patients and controls. 
Areas under the curve were estimated using the trapezoidal method.  
 
Glucose absorption during the hypertonic PD exchange test was estimated by simple mass 
balance. Resistance to insulin was estimated indirectly, according to the Homeostasis Model 
Assessment (HOMA) score [plasma insulin (mcUI/mL) 
*
 plasma glucose (mM/L)/22.5] [20].  
Statistics 
All comparisons were based on univariate, non-parametric tests. The degree of concordance 
between baseline estimations was analysed using Spearman's correlation coefficient and the t -test for 
paired data (systematic biases). Intragroup comparisons (changes versus baseline and oral versus 
placebo) were based on Wilcoxon's test. Comparisons between patients and controls were based on 
Fisher's (categorical) and Mann–Whitney U (numerical) tests. Numerical correlations were analysed 
using Spearman's correlation test. P -values ≤ 0.05 were considered to be significant. For graphic 
representation we used mean values ± SEM. The SPSS software 14.0 was used to produce statistical 
analysis.  
Results 
Baseline estimations 
Main baseline hormonal estimations in the three tests are presented in Table 1. Plasma levels of 
both PYY (1–36) and PYY (3–36) were significantly higher in patients than in controls in each test. In 
patients, baseline PYY (1–36) and PYY (3–36) levels showed a good concordance between the three 
estimations performed, with correlation coefficients higher than 0.70 (P < 0.02) in all cases 
(Spearman), and no evidence of systematic biases. Also, the correlation coefficients between PYY (1–
36) and PYY (3–36) levels in each test were high: 0.95 for the oral test, 0.90 for the placebo test and 0.92 
for the intraperitoneal glucose test (P < 0.001 any). In reference to healthy controls, the correlation 
between PYY (1–36) and PYY (3–36) was also good. However, baseline plasma PYY (3–36) levels came 
out to be significantly lower during the placebo test than during the oral feeding test (Table 1). There 
was also more variability in the correlations between baseline plasma levels of PYY (1–36) and PYY (3–
36) [ r = 0.38 ( P = 0.31) in the oral test, r = 0.78 (P  = 0.03) in the placebo test], in the control group.  
  
Table 1. Baseline plasma hormone levels 
  Patients  Controls  P  
    
PYY (1–36) (pg/mL)         
Oral feeding test  406 (237–1244)  100 (61–179)  0.001  
Placebo test  432 (312–1247)  73 (52–164)  0.001  
Hypertonic glucose-based dialysate test  460 (265–910)      
PYY (3–36) (pg/mL)         
Oral feeding test  267 (161–521)  70 (51–89)  0.001  
Placebo test  244 (153–358)  56 (37–71) *  0.001  
Hypertonic glucose-based dialysate test  235 (138–542)      
Total ghrelin (pg/mL)        
Oral feeding test  960 (728–1302)  731 (399–1016)  0.06  
Oral placebo test  933 (784–1252)  669 (411–1023)  0.02  
Hypertonic glucose-based dialysate test  1022 (696–1238)      
Acylated ghrelin (pg/mL)        
Oral feeding test  97 (35–185)  140 (43–193)  0.07  
Oral placebo test  106 (19–188)  112 (39–227)  0.97  
Hypertonic glucose-based dialysate test  128 (28–211)      
Quotient total ghrelin/PYY (1–36)        
Oral feeding test  1.90 (0.90–4.57)  7.44 (3.64–14.56)  0.001  
Oral placebo test  2.31 (0.97–4.01)  9.84 (2.51–20.95)  0.001  
Hypertonic glucose-based dialysate test  1.61 (1.19–3.78)      
Quotient acylated ghrelin /PYY (3–36)        
Oral feeding test  0.45 (0.10–0.91)  2.03 (0.92–3.00)  0.001  
Oral placebo test  0.46 (0.09–0.76)  2.14 (0.74–3.85)  0.001  
Hypertonic glucose-based dialysate test  0.52 (0.23–0.93)      
Leptin (ng/mL)        
Oral test  41.4 (3.6–170.8)  9.3 (3.0–24.1)  0.04  
Placebo test  36.0 (0.7–103.6)  11.1 (2.7–30.5)  0.08  
Hypertonic glucose-based dialysate test  36.2 (3.3–94.9)  –    
Insulin (mcUI/mL)        
Oral test  14.5 (5.1–25.3)  9.5 (3.7–16.1)  0.04  
Placebo test  13.1 (6.9–20.4)  9,7 (2.8–15.0)  0.09  
Hypertonic glucose-based dialysate test  13.5 (6.7–22.5)  –    
HOMA score        
Oral test  3.03 (1.70, 7.81)  2.26 (0.75, 4.05)  0.12  
Placebo test  3.02 (1.89, 4.55)  2.61 (0.57, 3.83)  0.24  
Hypertonic glucose-based dialysate test  2.52 (1.58, 5.71)  –    
Plasma growth hormone (ng/mL)        
Oral  3.52 (0.18, 9.50)  0.72 (0.01, 2.20)  0.08  
Placebo  2.51 (0.19, 5.80)  1.35 (0.01, 6.53)  0.17  
Hypertonic glucose-based dialysate test  2.19 (0.16, 5.30)  –    
Plasma cortisol (mcgr/dL)        
Oral  14.1 (5.0, 21.9)  12.3 (10.0, 16.2)  0.51  
Placebo  16.3 (7.1, 20.0)  13.3 (9.4, 18.8)  0.41  
Hypertonic glucose-based dialysate test  14.4 (5.4, 22.9)  –    
    
 
Figures denote median values (range) at baseline of each test. Comparisons by the Mann–Whitney U -test. *P = 0.04 versus 
oral feeding test. Other intragroup differences not significant. 
 
 
  
We observed no clear correlation between baseline plasma levels of PYY (1–36) or PYY (3–36) on 
one side, and of total or acylated ghrelin levels on the other. Quotients between baseline values of 
ghrelin and PYY are presented in Table 1. Values proved consistent in the three tests performed, 
depicting a markedly lower orexigenic pattern in patients than in controls.  
 
In patients, we observed a significant direct correlation between baseline plasma levels of cortisol 
on one side, and PYY (1–36) (r = 0.87, P = 0.002) and PYY (3–36) (r = 0.88, P = 0.001) on the other, 
while this correlation was nonsignificant in controls. Baseline PYY (1–36) or PYY (3–36) plasma levels 
showed no apparent correlation with leptin, insulin or GH levels or the HOMA score. Nor did we 
detect any correlation between PYY (1–36) and PYY (3–36) levels and the main demographic variables 
scrutinized (age, gender, GFR, time on dialysis, body mass index).  
 
All patients were apparently well nourished, as estimated from subjective global assessment. 
Also, as previously stated, no patient reported anorexia during the study period, although we did not 
apply any normalized anorexia score. One patient and one control were obese (body mass index >30). 
Table 2 displays the selected biochemical inflammatory and nutritional markers. None of them 
showed a correlation with plasma levels of PYY (1–36) or PYY (3–36) , either in patients or healthy 
controls.  
Table 2. Inflammatory and nutritional markers 
  Patients  Controls  P  
    
Interleukin-6 (pg/mL)  7.4 (0.0–32.9)  0.0 (0.0–8.0)  0.006  
C-reactive protein (mg/L)  2.1 (0.2–13.8)  0.7 (0.2–1.4)  0.08  
Albumin (g/L)  41 (36–46)  45 (40–49)  0.08  
Prealbumin (mg/dL)  37 (29–41)  41 (32–48)  0.22  
Cholesterol (mg/dL)  183 (119–201)  195 (130–241)  0.35  
Triglycerides (mg/dL)  165 (84–460)  102 (54–276)  0.15  
IGF-1 (ng/mL)  140 (111–289)  79 (63–118)  0.01  
    
 
Figures denote median values (range) at baseline of each test. Comparisons by the Mann–Whitney U -test. 
In patients, median glucose absorption 120 min after the hypertonic glucose peritoneal exchange 
was 36.9 g (range 29.3–56.8). 
PYY (1–36) 
Plasma levels of PYY (1–36) in response to the mixed meal, placebo and intraperitoneal glucose are 
presented in Figures 1 a, b and 3 a, respectively. Only healthy controls showed a response to oral 
intake (Figure 1 b), while there was no apparent change of PYY (1–36) levels after oral feeding (Figure 
1 a) or intraperitoneal glucose (Figure 3 a), in patients.  
  
 
 
 
Fig. 1. (a) Plasma levels of PYY (1–36) after placebo or a mixed meal in patients. Values denote mean ± SEM. 
*P < 0.05 versus 
baseline. Placebo versus oral, P = 0.028 at 30 min; other differences NS. (b) Plasma levels of PYY (1–36) after placebo or a 
mixed meal in controls. Values denote mean ± SEM. *P < 0.05 versus baseline. **P = 0.09 versus baseline. Placebo versus oral, 
P < 0.05 at 30 and 45 min; other differences NS. 
 
 
 
Fig. 2. (a) Plasma levels of PPY (3–36) after placebo or a mixed meal in patients. Values denote mean ± SEM. Differences NS. 
(b) Plasma levels of PYY (3–36) after placebo or a mixed meal in controls. Values denote mean ± SEM. 
*P < 0.05 versus 
baseline. Placebo versus oral, P < 0.02 at any point beyond baseline. 
  
 
 
 
Fig. 3. (a) Plasma levels of PPY (1–36) after placebo or intraperitoneal glucose in patients. Values denote mean ± SEM. 
Differences NS. (b) Plasma levels of PYY (3–36) after placebo or intraperitoneal glucose in patients. Values denote mean ± 
SEM. Differences NS. 
In patients, peak plasma levels of PYY (1–36) were 400 (272–1269) (meal), 462 (277–894) 
(placebo) and 480 pg/mL (321–950) (intraperitoneal glucose) (NS). In controls, the observed peak 
values were 141.5 (81–198) (meal) and 92.5 pg/mL (46–219) (placebo) (P = 0.04) (patients versus 
controls P < 0.001 any comparison).  
 
In patients, the AUC values were 43560 (29715–128227) (meal), 50430 (32685–103477) 
(placebo) and 51142 pg/mL min (32025–100080) (intraperitoneal glucose) (NS). In controls, 
corresponding values were 14865 (8032–19822) (meal) and 8992 pg/mL min (4455–21382) 
(placebo) (P = 0.06). Differences between patients and controls were significant (P < 0.001) for each 
test.  
PYY (3–36) 
Plasma levels of PYY (3–36) in response to the mixed meal, placebo and intraperitoneal glucose are 
presented in Figures 2 a, b and 3 b, respectively. In patients, we observed no significant change in 
PYY (3–36) levels after oral intake or intraperitoneal glucose. In contrast, controls displayed a clear rise 
of PYY (3–36) levels after oral intake (Figure 2 b).  
 
In patients, peak plasma levels of PYY (3–36) were 271 (191–534) (meal), 234 (138–541) (placebo) 
and 247 pg/mL (130–483) (intraperitoneal glucose) (NS). In controls, the observed peak values were 
92.5 (59–135) (meal) and 46.5 pg/mL (30–66) (placebo) (P = 0.02) (patients versus controls P < 
0.001 any comparison).  
 
In patients, the AUC values for PYY (3–36) were 33982 (21277–60195) (oral), 28785 (17040–
41182) (placebo) and 29 659 pg/mL min (14542–47707) (intraperitoneal glucose) (NS). In controls, 
corresponding values were 9086 (6412–14970) (oral) and 4984 pg/mL min (3142–6772) (placebo) ( 
P = 0.012) (patients versus controls P < 0.001 any comparison).  
  
Discussion 
CRF is frequently complicated by a catabolic and inflammatory state, resulting in progressive 
wasting and significant mortality rates [2]. Many factors (related to renal insufficiency itself, dialysis 
therapies and associated comorbidities) contribute to this complex condition, but malnutrition is a 
cardinal feature of the syndrome [1,3]. Anorexia is a prominent factor leading to malnutrition in CRF 
[3], and PD bears some specific features that may aggravate this symptom [4], including a significant 
risk of inadequacy of dialysis once residual renal function declines [21], pressure-related satiation 
secondary to the presence of intra-abdominal dialysate [22] and a direct inhibition of appetite by 
glucose- and amino acid-based dialysis solutions [22–24]. In fact, low appetite is an almost universal 
feature in patients undergoing this therapy [25].  
 
In recent years, a considerable interest has been raised on the role of humoral mediators of 
appetite in the pathogenesis of anorexia of CRF [5]. However, the available evidence is fragmentary 
and unconclusive, and often based on cross-sectional screening of plasma levels of different 
mediators of appetite. Leptin and ghrelin have received most attention, although other orexigenic and 
anorexigenic factors have also been scrutinized [5]. Leptin levels are commonly increased in patients 
with CRF, keeping an inverse correlation with GFR, although the basic relationship with body fat 
mass is also preserved, in this setting. Patients undergoing PD display particularly elevated leptin 
levels, as a consequence of the increased fat mass and hyperinsulinism frequently observed in these 
individuals [ 8 ] and, probably, of a direct stimulatory effect of intraperitoneal glucose on adipocytes 
[26]. Similar to normal individuals, leptin secretion is not affected by oral intake in the short term 
[12]. The actual role of this adipokine as a mediator of anorexia and malnutrition in patients on PD is 
still a matter of controversy [9,10,27 ]. On the other hand, plasma levels of total, but not acylated 
ghrelin, are frankly elevated in CRF [11], without significant differences according to the mode of 
dialysis therapy [28]. The role of ghrelin in the pathogenesis of anorexia of CRF has not been 
established, but anorexic PD patients have been claimed to present relatively low plasma ghrelin 
levels [29], and the exogenous administration of ghrelin has been proved to increase appetite, in this 
setting [13].  
 
L cells in the distal intestine are seemingly the main source of PYY secretion. The peptide is 
secreted postprandially in proportion to the caloric load delivered, with a macronutrient potency of 
lipids being greater than that of carbohydrates, which is greater than that of proteins [30]. Secretion 
decays to reach nadir plasma levels during fasting periods, rising significantly after meals [31]. 
Plasma PYY levels start to increase within 15 min of a meal, peak at ∼90 min and then remain 
elevated for up to 6 h [32]. A significant fraction of the full peptide (PYY 1–36 ) is rapidly proteolyzed 
by DPP4, and the cleaved product, PYY 3–36 , represents the bioactive fraction of the hormone [15]. 
The ability of PYY 3–36 to induce satiation has been established in several recent studies, supporting a 
role for this peptide as a promising therapy for obesity. Peripheral PYY 3–36 administration, at doses 
generating physiologic postprandial blood excursions, reduces food intake and body weight in rats 
[16]. In obese humans, intravenous infusion of PYY 3–36 replicating postprandial concentrations 
inhibits appetite, decreasing buffet-meal intake by one-third, without causing nausea, affecting food 
palatability or altering fluid intake [18]. This is in contrast to the well-known inability of leptin and 
insulin to induce anorexia, in this subset. Furthermore, baseline levels of PYY 3–36 are lower in obese 
than in lean individuals, lending further support to the potential role for this peptide in the 
pathogenesis of obesity [18,33,34]. The initial reports on the appetite-inhibiting effects of PYY 3–36 
surprised some investigators, because central administration of either PYY 1–36 or PYY 3–36 had been 
previously demonstrated to stimulate food intake [35]. The explanation to this apparent paradox 
appears to respond to Y receptor (YR) subtype selectivity and accessibility issues [15,16]. As such, 
the orexigenic effects of PYY 1–36 could be mediated by the interaction of this peptide with receptors 
Y1R and Y5R, which are expressed in the hypothalamic paraventricular nucleus and appear to 
mediate NPY-induced feeding. PYY 3–36 selectively activates Y2R and Y5R, and central 
administration of this peptide might increase food intake through the latter receptor. On the other 
hand, circulating PYY 3–36 may interact selectively with Y2R in the hypothalamic arcuate nucleus, an 
area believed by some to be accessible to blood-borne factors. In the hypothalamus, Y2R is a 
presynaptic autoinhibitory receptor of orexigenic neurons expressing both NPY and agouti-related 
protein (AGRP), so-named NPY/AGRP neurons. Thus, according to this hypothesis, circulating PYY 
3–36 reduces food intake by inhibiting NPY/AGRP neurons through Y2R, thereby depressing adjacent 
anorectic melanocortin-producing cells, which are inhibited by NPY/AGRP neurons [16]. Consistent 
with this, the effects of circulating PYY 3–36 on feeding behaviour are abolished by pharmacologic or 
genetic blockade of Y2R [16,36].  
 
Our results show that fasting plasma levels of PYY 1–36 and PYY 3–36 are markedly increased in 
patients with CRF treated with PD, when compared with matched healthy controls. Moreover, plasma 
levels of PYY 1–36 and PYY 3–36 do not appear to change after a standardized meal or intraperitoneal 
glucose infusion in these patients, as opposed to the observed postprandial increase observed in 
controls. To our knowledge, this is the first study estimating plasma levels of PYY 1–36 and PYY 3–36 
both fasting and after a mixed meal in patients with CRF treated with dialysis. Our results show some 
similarities with those observed in patients with anorexia nervosa [19,37], suggesting that PYY may 
play some role in the anorexia of CRF. The strong negative association between fasting PYY levels 
and fat intake observed in girls with anorexia nervosa [19] may explain the marked reductions in fat 
intake observed in these subjects [19,38]. Similar to obese individuals, and again in contrast to the 
cases of leptin and ghrelin [39,40], the nutritional drive of patients with anorexia nervosa appears to 
be responsive to changes in plasma PYY levels. In patients with CRF, plasma levels of PYY (both 
PYY 1–36 and PYY 3–36 ) and total ghrelin [28] are increased, while those of acylated ghrelin are not 
[11,12]. This association of markedly increased levels of PYY 3–36 with normal levels of acylated 
ghrelin sets a potentially anorexigenic scenery, in these patients.  
 
We have previously shown that plasma total ghrelin levels decreased modestly, and plasma acyl-
ghrelin more markedly, after a standardized oral feeding in patients with CRF treated with PD [12]. 
However, these changes were significantly attenuated, when compared with healthy controls, 
indicating that ghrelin secretion is partially refractory to the acute inhibitory effect of oral intake, in 
these patients. In a similar way, neither PYY 1–36 nor PYY 3–36 levels responded to oral intake, 
indicating a marked disruption in the normal secretory patterns of this peptide. Again, the 
combination of an attenuated but still significant decay of acylated ghrelin secretion with persistently 
elevated PYY 3–36 levels in the postprandial period could contribute to early satiety and malnutrition, 
in these patients.  
 
Intravenous infusion of PYY to normal subjects has been found to cause a significant decrease in 
GFR [41]. This could give a role for increased PYY levels in the decline of residual renal function of 
CRF patients. On the other hand, in the control group, baseline serum PYY (3–36) levels were 
moderately but significantly higher before meal ingestion than before placebo ingestion. This 
difference could be fortuitous, but could also follow increased vagal activity due to an anticipation of 
food, in a similar way as insulin secretion [42]. The relevance of cephalic–vagal stimulation in the 
control of gastrointestinal peptides has been demonstrated for other peptides, including ghrelin [43], 
using the technique of modified sham feeding or the ‘chew and spit’ technique, in which foods are 
smelled, chewed and tasted, but not swallowed.  
 
In summary, we have found that plasma levels of PYY 1–36 and PYY 3–36 are markedly increased, 
both fasting and after a standardized oral feeding, in patients with CRF treated with dialysis, when 
compared with healthy controls. Plasma PYY 1–36 and PYY 3–36 do not show the expected increase 
after a standardized oral feeding in patients with CRF treated with dialysis, indicating a severe 
disruption in the physiologic mechanisms that regulate appetite in these patients. Increased plasma 
levels of PYY could contribute to the anorexia and malnutrition of CRF.  
Acnowledgements 
The author thanks Mr Ramón Pensado and Ms Rosa Nemiña for technical assistance. This work was supported 
by grants PI051024 and PI070413 from Instituto de Salud Carlos III, and PS07/12 and 2006/27 from Xunta de 
Galicia. 
 
Conflict of interest statement.  
We declare no conflict of interest for this manuscript. We have no involvement that might rise the question of 
bias in the work reported or in the conclusions, implications or opinions exposed. We also state that the data 
presented in the manuscript are original. Also, the main data have not been published elsewhere in whole or part, 
except in abstract form. We specifically state that part of the crude data on baseline hormone levels (but not 
those subject of the present study) depicted in Table 1 were presented in the journal Kidney International in 
2005, as stated in the Method description (page 6, Section Population and Method-Protocol).  
  
References 
1. Fouque D, Kopple JD. Malnutrition and dialysis. In: Hörl WH, Koch, KM, Lindsay RM, Ronco C and 
Winchester JF (eds). Replacement of Renal Function by Dialysis. Dordrecht: Kluwer, 2004, 1013–1039 
2. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002; 11: 437–439  
3. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995; 6: 1329–1341 
4. Wang T, Heimburger O, Bergstrom J et al. Nutritional problems in peritoneal dialysis: an overview. Perit 
Dial Int 1999; 19: S297–S303 
5. Bossola M, Tazza L, Giungi S et al. Anorexia in haemodialysis patients: an update. Kidney Int 2006; 70: 
417–422 
6. Coll AP, Farooqi IS, O’Rahilly S. The hormonal control of food intake. Cell 2007; 129: 251–262 
7. Heimbürger O, Stenvinkel P. Adipokines in chronic kidney disease—fat tissue gives nephrologists a 
message. Perit Dial Int 2005; 25: 340–342 
8. Pérez Fontan M, Rodríguez-Carmona A, Cordido F et al. Hyperleptinemia in uremic patients undergoing 
conservative treatment, peritoneal dialysis and hemodialysis: a comparative analysis. Am J Kidney Dis 1999; 
34: 824–831 
9. Stenvinkel P, Lindholm B, Lohnqvist F et al. Increases in serum leptin during peritoneal dialysis are 
associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303–1309 
10. Rodríguez-Carmona A, Pérez-Fontán M, Cordido F et al. Hyperleptinemia is not correlated with markers of 
protein malnutrition in chronic renal failure. A cross-sectional study in predialysis, peritoneal dialysis and 
hemodialysis patients. Nephron 2000; 86: 274–280 
11. Yoshimoto A, Mori K, Sugawara A et al. Plasma ghrelin and desacyl ghrelin concentratins in renal failure. J 
Am Soc Nephrol 2002; 13: 2748–2752 
12. Pérez Fontán M, Cordido F, Rodríguez-Carmona A et al. Acute plasma ghrelin and leptin responses to oral 
feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney 
Int 2005; 68: 2877–2885 
13. Wynne K, Bloom SR. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appettite control. 
Nat Clin Pract Endocrino Metabol 2006; 2: 612–620 
14. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. 
Endocr Rev 2006; 27: 719–727 
15. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13–23 
16. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY (3–36) physiologically inhibits food intake. 
Nature 2002; 418: 650–654 
17. Chaudhri OB, Field BCT, Bloom S. From gut to mind—hormonal satiety signals and anorexia nervosa. J 
Clin Endocrinol Metab 2006; 91: 797–798 
18. Batterham RL, Cohen MA, Ellis SM et al . Inhibition of food intake in obese subjects by peptide YY 3–36. 
New Engl J Med 2003; 349: 941–948 
19. Misra M, Miller KK, Tsai P et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J 
Clin Endocrinol Metab 2006; 91: 1027–1033 
20. Matthews DR, Hosker HP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-
cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–
419 
21. Szeto CC, Lai KN, Wong TYH et al. Independent effects of residual renal function and dialysis adequacy on 
nutritional status and patients outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999; 
34: 1056–1064 
22. Van Vlem BA, Schoonjans RS, Struijk DG et al. Influence of dialysate on gastric emptying time in 
peritoneal dialysis patients. Perit Dial Int 2002; 22: 32–38 
23. Mamoun AH, Anderstam B, Södersten P et al. Influence of peritoneal dialysis solutions with glucose and 
aminoacids on ingestive behavior in rats. Kidney Int 1996; 49: 1276–1282 
24. Zheng ZH, Sederholm F, Anderstam B et al. Acute effects of peritoneal dialysis solutions on appetite in non-
uremic rats. Kidney Int 2001; 60: 2392–2398 
25. Sutton D, Higgins B, Stevens JM. Continuous ambulatory peritoneal dialysis patients are unable to increase 
dietary intake to recommended levels. J Ren Nutr 2007; 17: 329–335 
26. Teta D, Maillard M, Tedjani A et al. The effect of pH-neutral peritoneal dialysis fluids on adipokine 
secretion from cultured adipocytes. Nephrol Dial Transplant 2007; 22: 862–869 
27. Bossola M, Muscaritoli M, Valenza V et al. Anorexia and serum leptin levels in hemodialysis patients. 
Nephron Clin Pract 2004; 97: c76–c82 
28. Pérez Fontán M, Cordido F, Rodríguez-Carmona A et al. Plasma ghrelin levels in patients undergoing 
haemodialysis and pertitoneal dialysis. Nephrol Dial Transplant 2004; 19: 2095–2100 
29. Aguilera A, Cirugeda A, Amair R et al. Ghrelin plasma levels and appetite in peritoneal dialysis patients. 
Adv Perit Dial 2004; 20: 194–199 
30. Degen L, Oesch S, Casanova M et al. Effect of peptide YY 3–36 on food intake in humans. Gastroenterology 
2005; 129: 1430–1436 
31. Soffer EE, Adrian TE, Launspach J et al. Meal-induced secretion of gastrointestinal regulatory peptides is 
not affected by sleep. Neurogastroenterol Motil 1997; 9: 7–12 
32. Adrian TE, Ferri GL, Bacarese-Hamilton AJ et al. Human distribution and release of a putative new gut 
hormone, peptide YY. Gastroenterology 1985; 89: 1070–1077 
33. Korner J, Leibel RL. To eat or not to eat—how the gut talks to the brain. New Engl J Med 2003; 349: 926–
928 
34. Álvarez-Bartolomé M, Borque M, Martínez-Sarmiento J et al. Peptide YY secretion in morbidly obese 
patients before and after vertical banded gastroplasty. Obes Surg 2002; 12: 324–327 
35. Hagan M. Peptide YY: a key mediator of orexigenic behavior. Peptides 2002; 23: 377–382 
36. Scott V, Kimura N, Stark JA et al . Intravenous peptide YY 3–36 and Y2 receptor antagonism in the rat: 
effects on feeding behaviour. J Neuroendocrinol 2005; 17: 452–457 
37. Pfluger PT, Kampe J, Castaneda TR et al. Effect of human body weight changes on circulating levels of 
peptide YY and peptide YY 3–36. J Clin Endocrinol Metab 2007; 92: 583–588 
38. Affenito SG, Dohm FA, Crawford PB et al. Macronutrient intake in anorexia nervosa: the national heart, 
lung, and blood institute growth and health study. J Pediatr 2002; 141: 701–705 
39. Nedvidkova J, Krykorkova I, Bartak V et al. Loss of meal-induced decrease in plasma ghrelin levels in 
patients with anorexia nervosa. J Clin Endocrinol Metab 2003; 88: 1678–1682 
40. Misra M, Miller KK, Kuo K et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and 
healthy adolescents. Am J Physiol Endocrinol 2005; 289: E373–E381 
41. Playford RJ, Mehta S, Upton P et al. Effect of peptide YY on human renal function. Am J Physiol 1995; 268: 
F754–F759 
42. Hojlund K, Wildner-Christensen M, Eshoj O et al. Reference intervals for glucose, β-cell polypeptides and 
counterregulatory factors during prolonged fasting. Am J Physiol Endocrinol Metab 2001; 280: E50–E58 
43. Arosio M, Ronchi CL, Beck-Peccoz P et al. Effects of modified sham feeding on ghrelin levels in healthy 
human subjects. J Clin Endocrinol Metab 2004; 89: 5101–5104 
 
